海外の治験の状況「1」での検索結果
379件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- The effect of anti-latency reversing therapy and broadly neutralizing antibodies on the HIV-1 reservoir in patients on antiretroviral therapy - a randomized trial (ROADMAP)
- HIV infection MedDRA version: 20.0 Level: LLT Classification code 10020180 Term: HIV positive System Organ Class: 100000004848 MedDRA version: 20.1 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Denmark, Germany, United States
- 2016-08-03
Authorised
- A multicentre and international trial of a new treatment regimen containing paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for people with chronic hepatitis C virus genotype 1 infection and recent injection drug use or receiving opioid substitution therapy.
- Chronic hepatitis C virus genotype 1 infection MedDRA version: 19.0 Level: LLT Classification code 10072844 Term: Hepatitis C virus genotype 1a positive System Organ Class: 100000004848 MedDRA version: 19.0 Level: LLT Classification code 10072845 Term: Hepatitis C virus genotype 1b positive System Organ Class: 100000004848 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Australia, Canada, France, New Zealand, Norway, Switzerland
- 2016-07-08
Authorised
- A Phase 1 dose-finding and Phase 2 randomized double-blinded study evaluating if veliparib compared to placebo improves efficacy of caboplatin and etoposide combination in patients with untreated extensive stage small cell lung cancer
- Extensive Stage Disease Small Cell Lung Cancer (ED SCLC) MedDRA version: 19.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, Canada, Czech Republic, France, Hungary, Netherlands, Romania, Russian Federation, Spain, United States
- 2014-10-30
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective long term in the treatment of moderate to severe Ulcerative Colitis or Crohn's Disease (AIDA)
- Ulcerative colitis or Crohn's Disease MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2017-10-25
Authorised
- An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic mutations
- Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- France, Germany, Netherlands, United Kingdom, United States
- 2017-07-03
Authorised
- The Xenera-1 study tests xentuzumab in combination with everolimus and exemestane in post-menopausal women with hormone receptor positive and HER2-negative breast cancer that has spread
- HR+ / HER2- metastatic breast cancer and non-visceral disease MedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Portugal, Spain, United Kingdom, United States
- 2018-08-06
Authorised
- Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Premixed Insulin on Top of Metformin in Patients With Type 2 Diabetes and ± Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
- Patients with Type 2 Diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents(OADs) MedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Algeria, Argentina, Austria, Bulgaria, Czech Republic, Greece, India, Korea, Republic of, Kuwait, Macedonia, the former Yugoslav Republic of, Mexico, Romania, Saudi Arabia, Serbia, Spain, Sweden, Taiwan, Turkey, United Arab Emirates
- 2018-07-30
Authorised
- Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Premixed Insulin on Top of Metformin in Patients With Type 2 Diabetes and ± Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
- Patients with Type 2 Diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents(OADs) MedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Algeria, Argentina, Austria, Bulgaria, Czech Republic, Greece, India, Korea, Republic of, Kuwait, Macedonia, the former Yugoslav Republic of, Mexico, Romania, Saudi Arabia, Serbia, Spain, Sweden, Taiwan, Turkey, United Arab Emirates
- 2018-06-26
Authorised
- An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)
- Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0 Level: PT Classification code 10014989 Term: Epidermolysis bullosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Australia, Austria, France, Germany, Israel, Italy, Netherlands, United Kingdom, United States
- 2017-11-29
Authorised
- Pembrolizumab in Subjects with Advanced Recurrent Ovarian Cancer
- A:platinum-resistant or partially platinum-sensitive recurrent ovarian cancer (OC) who received 1 but no more than 3 prior lines of anticancer regimens/local standard following primary or interval debulking surgery with a platinum free interval or treatment-free interval of 3-12 months based on last regimen received B:recurrent OC who received 3-5 prior lines of anticancer regimens/local standard with a platinum-free interval or treatment-free interval >or=3months based on last regimen received MedDRA version: 18.1 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, Finland, France, Germany, Israel, Japan, Lithuania, Netherlands, Russian Federation, South Africa, Spain, Sweden, United States
- 2015-12-16
